RecruitingPhase 2Drug trialA Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).